HCC therapies--lessons learned.

Area of Science:

• Oncology
• Hepatology
• Pharmacology

Background:

• Sorafenib, an antiangiogenic multikinase inhibitor, was the first systemic agent to improve overall survival in advanced hepatocellular carcinoma (HCC).
• Despite initial success, sorafenib's clinical benefits are modest, and challenges like patient heterogeneity and liver cirrhosis complicate treatment.
• The failure of subsequent phase III trials highlights the need for improved therapeutic strategies in HCC.

Purpose of the Study:

• To address the challenges in systemic therapy for advanced HCC.
• To emphasize the need for identifying specific molecular targets and developing matched agents.
• To advocate for refined clinical trial designs incorporating biomarker enrichment and prognostic stratification.

Main Methods:

• Review of existing data on sorafenib and subsequent targeted therapies in HCC.
• Analysis of factors contributing to treatment limitations, including molecular/clinical heterogeneity and cirrhosis-related toxicity.
• Discussion of strategies for future clinical trial design in HCC.

Main Results:

• Sorafenib demonstrated modest survival benefits in unselected HCC populations.
• Patient heterogeneity and liver cirrhosis significantly impact treatment efficacy and safety.
• Subsequent phase III trials have largely failed to show significant improvements.

Conclusions:

• There is an urgent need to identify specific driver targets in HCC.
• Development of matched agents with manageable toxicities, especially in patients with cirrhosis, is crucial.
• Biomarker-enriched patient selection and prognostic stratification are essential for successful future HCC clinical trials.